Default company panoramic image

Qrono Inc.

Qrono reformulates FDA approved medications with known safety and efficacy and creates new, long-acting medicines with improved clinical and economic benefits.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Pittsburgh, PA, USA
  • Currency USD
  • Founded November 2010
  • Employees 4
  • Website

Company Summary

Qrono reformulates FDA approved drugs and creates long-acting injectable (LAI) medications with improved clinical and economic benefits. Our pipeline focuses on therapeutic areas where LAIs offer high therapeutic and economic value. We reduce risk since we are starting with FDA approved drugs that have known safety and efficacy. We use the accelerated FDA 505(b)(2) regulatory process that enables approvals 3X as fast at 1/3 the cost of new drugs.


  • Larry 20zana
    CEO, Director, and Co-founder

    Larry Zana, MS, is a serial entrepreneur (5th start-up) and has comprehensive senior management experience in engineering, product development, sales and marketing, and operations. Mr. Zana has more than 20 years of commercialization experience including biotech / pharma. He led development of the world’s first commercial high content screening instrument, which now plays a major role in drug discovery with more than 400 units sold worldwide.

  • Default avatar
    Sam Rothstein, PhD
    CSO and Co-founder

    Sam Rothstein is the lead inventor of the technology and has more than 37 publications / presentations in this area. He has been developing deterministic predictive models for more than 10 years, and has validated our technology on more than 80 formulations across more than 40 active agents and 9 different polymers. He has developed and produced more than 10 distinct controlled-release medications and vaccines.

  • Default avatar
    Steven Little, PhD
    Co-founder and Consultant

    Steven Little, PhD, was trained at MIT by Dr. Bob Langer, the founder of the field of drug delivery. He is currently Professor and Dept. Chair at the Univ. of Pittsburgh and was awarded the prestigious 2012 Young Investigator Award from the Society of Biomaterials. He is the elected Chair, Drug Delivery Special Interest Group, Society for Biomaterials, and has 44 peer-reviewed publications, 8 patent applications (4 issued), and 28 invited talks.

  • E9307517 4aa1 48c0 9ac8 5bd164a218f7
    VP, Finance

    Dan Seitam, MBA, is a technology executive who has held several C-level leadership positions (CEO, COO, CFO) in a variety of technology startups. He co-founded three companies and has worked in multiple industries that include healthcare IT, business analytics, embedded software for consumer products, wired / wireless broadband systems and storage software.


  • Default avatar
    David Smith (General Counsel) and Ray Miller (IP), Pepper Hamilton LLP
    Default avatar
    James Cunningham, Alpern Rosenthal

Previous Investors

  • Default avatar
    Idea Foundry
    Default avatar
    Private individuals
    Default avatar
    C-Leveled Associates Holdings